LeMaitre Vascular Reports Record Q2 2026 Results Driven by Artegraft Global Expansion
核心洞察
LeMaitre Vascular posted Q2 2026 sales of $70.4 million, a 10% organic increase, with Artegraft (搜索) sales surging 34% to account for 21% of total revenue.
Gross margin expanded 210 basis points to 72.1%, while operating income rose 26% to a record $20.4 million, representing a 29% operating margin.
The company raised its 2026 Artegraft (搜索) sales forecast to $11 million and now has regulatory approvals in 56 countries, with recent additions including Vietnam, Morocco, and Turkey.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) reported second-quarter 2026 financial results on August 4, 2026, posting record sales and operating income fueled by the accelerating international launch of its Artegraft (搜索) biologic vascular graft. The Burlington, Massachusetts-based company, a provider of devices and implants for peripheral vascular disease (搜索), delivered $70.4 million in quarterly net sales, representing 10% organic growth over the same period in 2025.
Chairman and CEO George LeMaitre highlighted the Artegraft (搜索) performance as the quarter's defining achievement. "Our focus on the Artegraft international launch paid off in Q2. The product is now approved in 56 countries, accounting for 21% of sales. So our largest product is now our fastest-growing product," LeMaitre said.
Financial Performance and Margin Expansion
Gross margin reached 72.1%, an increase of 210 basis points year-over-year, driven by higher average selling prices, favorable product mix shift, and operational efficiencies. Operating income climbed 26% to a record $20.4 million, yielding a 29% operating margin. Net income rose 24% to $17.1 million, with diluted earnings per share of $0.74, up 23% from $0.60 in the prior-year quarter.
The company benefited from disciplined headcount management, with 660 employees at June 30, 2026, compared to 658 a year earlier. Cash and marketable securities totaled $376.2 million at quarter-end, up $9.0 million sequentially.
Product and Geographic Highlights
Artegraft (搜索) sales increased 34% in the quarter, with management raising the full-year 2026 Artegraft revenue forecast to $11 million, up from $4 million in 2025. International Artegraft sales advanced sequentially from $2.1 million to $2.8 million.
Other product categories also posted records: grafts grew 23%, carotid shunts increased 18%, and patches rose 4%. Allograft revenues grew 17%, though cardiac allograft growth was constrained by tissue supply limitations. Catheter sales declined 11%, which management attributed to recall-driven overstocking by customers in the second quarter of 2025—a transient headwind. Excluding catheters, organic growth was 12%.
Geographically, Europe, Middle East, and Africa (EMEA) and Asia Pacific (APAC) each grew 18%, while the Americas grew 5%, or 8% excluding catheters. The company received new Artegraft (搜索) regulatory approvals in Vietnam, Morocco, and Turkey during the quarter.
Operational Developments and Strategic Initiatives
LeMaitre is undertaking six international warehouse expansions as part of a "relocalization" strategy that has significantly reduced shipping costs. George LeMaitre noted that shipping costs drop from approximately $55 per shipment from Frankfurt to $5 from Madrid, contributing to European gross margin expansion of 5 to 9 percentage points year-over-year. European segment profitability rose approximately 70%.
On the regulatory front, the FDA indicated that a clinical trial will likely be required for the company's QuickStitch (搜索) device, potentially pushing any launch several years out. George LeMaitre acknowledged that LeMaitre is "not historically a clinical trial company" and said management needs time to decide whether to invest in the required trial.
The FDA also re-audited the company's New Jersey facility, issuing additional quality observations, though production and shipments have not been disrupted.
To address cardiac allograft supply constraints, the company is consolidating tissue processing at its Burlington, Massachusetts headquarters and deploying DonorIQ artificial intelligence tools to optimize procurement.
Business Outlook and Guidance
LeMaitre provided updated guidance reflecting persistent foreign exchange headwinds, Middle East export disruptions, and cardiac allograft supply constraints. For the full year 2026, the company projects revenue of $276.3 million at the midpoint, representing 11% reported and 11% organic growth. Gross margin is expected at 72.4%, with operating income of $76.8 million (28% operating margin) and EPS of $2.89, representing 21% adjusted growth.
For the third quarter of 2026, guidance calls for sales of $66.3 million to $68.3 million (midpoint $67.3 million, +10% reported, +11% organic), gross margin of 72.2%, and EPS of $0.66 to $0.71.
The Board of Directors approved a quarterly dividend of $0.25 per share, payable on September 3, 2026, to stockholders of record on August 20, 2026. The company also has an active share repurchase program authorizing up to $100 million through February 2027.
Looking ahead, LeMaitre continues to invest in its sales force, pursue regulatory approvals in Korea, Brazil, India, and Japan, and maintain an active M&A pipeline targeting open vascular businesses or cardiac surgery expansion opportunities with revenues between $15 million and $150 million.